Michael W. Knitz

Dec 31, 2024 | jitc.bmj.com | Jacob Gadwa |Justin Yu |Miles Piper |Michael W. Knitz

MethodsMurine MOC2 and P029 HNSCC and PK5L1940 pancreatic cell lines were used for in vivo studies. All cells were cultured at 37°C and 5% CO2 in appropriate media; DMEM-F12:IMDM (1:2) supplemented with 10% FBS and 1% primocin/fungin (InvivoGen), 1.75 µg EGF, 20 µg hydrocortisone, and 0.1% insulin for MOC2; DMEM-F12 supplemented with 10% FBS and 1% primocin/fungin for P029; RPMI1640 supplemented with 10% FBS and 1% primocin/fungin for PK5L1940.

Nov 2, 2024 | nature.com | Diemmy Nguyen |Laurel Darragh |Mike W. Matsumoto |Benjamin Van Court |Alexander Nguyen |Shilpa Bhatia | +7 more

AbstractThe EphB4-ephrinB2 signaling axis has been heavily implicated in metastasis across numerous cancer types. Our emerging understanding of the dichotomous roles that EphB4 and ephrinB2 play in head and neck squamous cell carcinoma (HNSCC) poses a significant challenge to rational drug design. We find that EphB4 knockdown in cancer cells enhances metastasis in preclinical HNSCC models by augmenting immunosuppressive cells like T regulatory cells (Tregs) within the tumor microenvironment.

Nov 2, 2024 | nature.com | Diemmy Nguyen |Laurel Darragh |Mike W. Matsumoto |Benjamin Van Court |Alexander Nguyen |Shilpa Bhatia | +7 more

AbstractThe EphB4-ephrinB2 signaling axis has been heavily implicated in metastasis across numerous cancer types. Our emerging understanding of the dichotomous roles that EphB4 and ephrinB2 play in head and neck squamous cell carcinoma (HNSCC) poses a significant challenge to rational drug design. We find that EphB4 knockdown in cancer cells enhances metastasis in preclinical HNSCC models by augmenting immunosuppressive cells like T regulatory cells (Tregs) within the tumor microenvironment.

Oct 10, 2024 | nature.com | Laurel Darragh |Michael W. Knitz |Xiao-jing Wang

Correction to: Nature Communications, https://doi.org/10.1038/s41467-022-34676-w, published online 16 November 2022The original version of the manuscript contained an error in Supplementary Fig. 8c. In the original figure, “Tumor only:ENI” was mistakenly indicated as label for the heatmap in Supplementary Fig. 8c. Instead, this should have been labeled as “ENI:Tumor Only”. Supplementary Fig. 8 has been corrected in the updated version of the Supplementary Information file now available.

Sep 24, 2024 | biorxiv.org | Benjamin Van Court |Michael W. Knitz |Mark Ciccaglione |Brooke Neupert

AbstractRecently developed nanobubble ultrasound contrast agents are a promising tool for imaging and drug delivery in tumors. To better understand their unusual kinetics, we implemented a novel pixel clustering analysis, which provides unique information by accounting for spatial heterogeneity.